Organigram: Consensus Analyst Estimates For Q2 2021
Organigram Holdings (TSX: OGI) (NASDAQ: OGI) will be reporting their fiscal second quarter on April 13th before the market open. Analysts have a consensus C$4.14 12-month price target on the company, via a total of 14 analysts, with two analysts having strong buy ratings. Two analysts meanwhile have buy ratings, nine have hold ratings and one analyst has a sell rating. The street high comes from Stifel-GMP with a C$6 price target, and the lowest target sits at C$2.
Nine analysts have revenue estimates for the second quarter. The mean between all 9 is C$20.21 million; this number has been revised downwards from C$24.51 million at the start of the year. The highest revenue estimate is C$23.87 million from Alliance Global, while the lowest is C$16 million.
Onto EBITDA estimates, there are currently eight analysts who have second-quarter EBITDA estimates. The mean is currently negative C$5.39 million, with this number having been revised down from almost breakeven at the start of the year. Street high is a negative C$4.1 million EBITDA estimate and the lowest being negative C$6.9 million.
Analysts estimate that quarterly earnings per share will come in at negative C$0.03, with this number being slightly revised down from negative C$0.02 at the start of the year. Street high is negative C$0.01 and the lowest estimate is negative C$0.05 per share for the quarter.
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
